Trine Ørhøj Barkholt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Trine Ørhøj Barkholt has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Jouke Dijkstra
Division of Image Processing Leiden University Medical Center Leiden The Netherlands
6 shared publicationsMichael Maeng
Department of Cardiology Aarhus University Hospital Aarhus Denmark
5 shared publicationsNiels Holm
5 shared publicationsEvald Høj Christiansen
Department of Cardiology, Aarhus University Hospital Skejby, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark
4 shared publicationsBruce Webber
Intra, Auckland, New Zealand
3 shared publicationsEmil Holck
3 shared publications
Latest Publications
- 14 December 2024
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (5) , 1924-1936
Validation and clinical impact of motion-free PET imaging using data-driven respiratory gating and elastic PET-CT registration
Purpose Clinical whole-body (WB) PET images can be compensated for respiratory motion using data-driven gating (DDG). However, PET DDG images may still exhibit motion artefacts at the diaphragm if the CT is acquired in a different respiratory phase than the PET image. This study evaluates the combined use of PET DDG and a deep-learning model (AIR-PETCT) for elastic registration of CT (WarpCT) to the non attenuation- and non scatter-corrected PET image (PET NAC), enabling improved PET reconstruction. Methods The validation cohort included 20 patients referred for clinical FDG PET/CT, undergoing two CT scans: a free respiration CTfree and an end-expiration breath-hold CTex. AIR-PETCT registered each CT to the PET NAC and PET DDG NAC images. The image quality of PET and PET DDG images reconstructed using CTs and WarpCTs was evaluated by three blinded readers. Additionally, a clinical impact cohort of 20 patients with significant “banana” artefacts from FDG, PSMA, and DOTATOC scans was assessed for image quality and tumor-to-background ratios. Results AIR-PETCT was robust and generated consistent WarpCTs when registering different CTs to the same PET NAC. The use of WarpCT instead of CT consistently led to equivalent or improved PET image quality. The algorithm significantly reduced “banana” artefacts and improved lesion-to-background ratios around the diaphragm. The blinded clinicians clearly preferred PET DDG images reconstructed using WarpCT. Conclusion AIR-PETCT effectively reduces respiratory motion artefacts from PET images, while improving lesion contrast. The combination of PET DDG and WarpCT holds promise for clinical application, improving PET image evaluation and diagnostic confidence.
- 14 December 2024
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (5) , 1924-1936
Validation and clinical impact of motion-free PET imaging using data-driven respiratory gating and elastic PET-CT registration
Purpose Clinical whole-body (WB) PET images can be compensated for respiratory motion using data-driven gating (DDG). However, PET DDG images may still exhibit motion artefacts at the diaphragm if the CT is acquired in a different respiratory phase than the PET image. This study evaluates the combined use of PET DDG and a deep-learning model (AIR-PETCT) for elastic registration of CT (WarpCT) to the non attenuation- and non scatter-corrected PET image (PET NAC), enabling improved PET reconstruction. Methods The validation cohort included 20 patients referred for clinical FDG PET/CT, undergoing two CT scans: a free respiration CTfree and an end-expiration breath-hold CTex. AIR-PETCT registered each CT to the PET NAC and PET DDG NAC images. The image quality of PET and PET DDG images reconstructed using CTs and WarpCTs was evaluated by three blinded readers. Additionally, a clinical impact cohort of 20 patients with significant “banana” artefacts from FDG, PSMA, and DOTATOC scans was assessed for image quality and tumor-to-background ratios. Results AIR-PETCT was robust and generated consistent WarpCTs when registering different CTs to the same PET NAC. The use of WarpCT instead of CT consistently led to equivalent or improved PET image quality. The algorithm significantly reduced “banana” artefacts and improved lesion-to-background ratios around the diaphragm. The blinded clinicians clearly preferred PET DDG images reconstructed using WarpCT. Conclusion AIR-PETCT effectively reduces respiratory motion artefacts from PET images, while improving lesion contrast. The combination of PET DDG and WarpCT holds promise for clinical application, improving PET image evaluation and diagnostic confidence.
- 16 June 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (6) , e259211
Tuberculosis immune reconstitution syndrome (TB-IRIS) followed by recurring lymphadenitis up to 8 years post-antituberculous treatment
We present the case of a patient with HIV and tuberculosis (TB) coinfection who initially developed paradoxical TB immune reconstitution inflammatory syndrome (TB-IRIS) post-antituberculous treatment and post-antiretroviral therapy initiation. Despite being managed effectively, lymphadenitis recurred as many as three times over the course of several years. Due to consistent culture-negative lymph node biopsies, the recurring lymphadenitis was eventually deemed inflammatory rather than microbiological recurrences. Cessation of anti-TB treatment led to symptom remission followed by a long asymptomatic period, corroborating the immunological nature of the episodes. However, 5 and 6 years after cessation of anti-TB treatment, respectively, lymphadenitis returned. In both instances, her symptoms regressed without treatment with anti-TB drugs. This case underscores the complexities of managing TB-IRIS and the necessity of differentiating between paradoxical TB-IRIS and other paradoxical reactions for appropriate treatment decisions. Recognition of such distinctions is crucial in guiding effective therapeutic interventions in TB-HIV coinfection scenarios.
- 16 June 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (6) , e259211
Tuberculosis immune reconstitution syndrome (TB-IRIS) followed by recurring lymphadenitis up to 8 years post-antituberculous treatment
We present the case of a patient with HIV and tuberculosis (TB) coinfection who initially developed paradoxical TB immune reconstitution inflammatory syndrome (TB-IRIS) post-antituberculous treatment and post-antiretroviral therapy initiation. Despite being managed effectively, lymphadenitis recurred as many as three times over the course of several years. Due to consistent culture-negative lymph node biopsies, the recurring lymphadenitis was eventually deemed inflammatory rather than microbiological recurrences. Cessation of anti-TB treatment led to symptom remission followed by a long asymptomatic period, corroborating the immunological nature of the episodes. However, 5 and 6 years after cessation of anti-TB treatment, respectively, lymphadenitis returned. In both instances, her symptoms regressed without treatment with anti-TB drugs. This case underscores the complexities of managing TB-IRIS and the necessity of differentiating between paradoxical TB-IRIS and other paradoxical reactions for appropriate treatment decisions. Recognition of such distinctions is crucial in guiding effective therapeutic interventions in TB-HIV coinfection scenarios.
- Open Access
- 5 February 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 101 (4) , 787-797
Early healing after treatment of coronary lesions by thin strut everolimus, or thicker strut biolimus eluting bioabsorbable polymer stents: The SORT‐OUT VIII OCT study
Aims: Early healing after drug‐eluting stent (DES) implantation may reduce the risk of stent thrombosis. The aim of this study was to compare patterns of early healing after implantation of the thin strut everolimus‐eluting Synergy DES (Boston Scientific) or the biolimus‐eluting Biomatix Neoflex DES (Biosensors).Methods and Results: A total of 160 patients with the chronic or acute coronary syndrome were randomized 1:1 to Synergy or Biomatrix DES. Optical coherence tomography (OCT) was performed at baseline and at either 1‐ or 3‐month follow‐up. The primary endpoint was a coronary stent healing index (CSHI), a weighted index of strut coverage, neointimal hyperplasia, malapposition, and extrastent lumen. A total of 133 cases had OCT follow‐up and 119 qualified for matched OCT analysis. The median CSHI score did neither differ significantly between the groups at 1 month: Synergy 8.0 (interquartile range [IQR]: 3.0; 14.0) versus Biomatrix 8.5 (IQR: 4.0; 15.0) (p = 0.47) nor at 3 months: Synergy 6.5 (IQR: 2.0; 13.0) versus Biomatrix 6.0 (IQR: 4.0; 11.0) (p = 0.83). Strut coverage was 84.6% (IQR: 72.0; 97.9) for Synergy versus 77.6% (IQR: 70.1; 90.3) for Biomatrix (p = 0.15) at 1 month and 90.3% (IQR 79.0; 98.8) (Synergy) versus 83.9% (IQR: 77.5; 92.6) (Biomatrix) (p = 0.068) at 3 months. Pooled 1‐ and 3‐month coverage was 88.6% (IQR: 74.4; 98.4) for Synergy compared with 80.7% (IQR: 73.2; 90.8) for Biomatrix (p = 0.02).Conclusions: The early healing response after treatment with the Synergy or Biomatrix DES did not differ significantly as determined by a healing index. The Synergy DES showed overall better early stent strut coverage.
- 5 February 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 101 (4) , 787-797
Open AccessEarly healing after treatment of coronary lesions by thin strut everolimus, or thicker strut biolimus eluting bioabsorbable polymer stents: The SORT‐OUT VIII OCT study
Aims: Early healing after drug‐eluting stent (DES) implantation may reduce the risk of stent thrombosis. The aim of this study was to compare patterns of early healing after implantation of the thin strut everolimus‐eluting Synergy DES (Boston Scientific) or the biolimus‐eluting Biomatix Neoflex DES (Biosensors).Methods and Results: A total of 160 patients with the chronic or acute coronary syndrome were randomized 1:1 to Synergy or Biomatrix DES. Optical coherence tomography (OCT) was performed at baseline and at either 1‐ or 3‐month follow‐up. The primary endpoint was a coronary stent healing index (CSHI), a weighted index of strut coverage, neointimal hyperplasia, malapposition, and extrastent lumen. A total of 133 cases had OCT follow‐up and 119 qualified for matched OCT analysis. The median CSHI score did neither differ significantly between the groups at 1 month: Synergy 8.0 (interquartile range [IQR]: 3.0; 14.0) versus Biomatrix 8.5 (IQR: 4.0; 15.0) (p = 0.47) nor at 3 months: Synergy 6.5 (IQR: 2.0; 13.0) versus Biomatrix 6.0 (IQR: 4.0; 11.0) (p = 0.83). Strut coverage was 84.6% (IQR: 72.0; 97.9) for Synergy versus 77.6% (IQR: 70.1; 90.3) for Biomatrix (p = 0.15) at 1 month and 90.3% (IQR 79.0; 98.8) (Synergy) versus 83.9% (IQR: 77.5; 92.6) (Biomatrix) (p = 0.068) at 3 months. Pooled 1‐ and 3‐month coverage was 88.6% (IQR: 74.4; 98.4) for Synergy compared with 80.7% (IQR: 73.2; 90.8) for Biomatrix (p = 0.02).Conclusions: The early healing response after treatment with the Synergy or Biomatrix DES did not differ significantly as determined by a healing index. The Synergy DES showed overall better early stent strut coverage.
- Open Access
- 30 December 2021
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 99 (4) , 1075-1083
Bioresorbable magnesium scaffold in the treatment of simple coronary bifurcation lesions: The BIFSORB pilot II study
Objectives: To evaluate the feasibility, safety, and healing response of a magnesium‐based bioresorbable scaffold (BRS) in the treatment of simple bifurcation lesions using the single stent provisional technique.Background: BRS may hold potential advantages in the treatment of coronary bifurcation lesions, however low radial strength and expansion capacity has been an issue with polymer‐based scaffolds. The magnesium BRS may prove suitable for bifurcation treatment as its mechanical properties are closer to those of permanent metallic drug‐eluting stents.Methods: The study was a proof‐of‐concept study with planned inclusion of 20 patients with stable angina pectoris and a bifurcation lesion involving a large side branch (SB) > 2.5 mm with less than 50% diameter stenosis. Procedure and healing response were evaluated by optical coherence tomography (OCT). The main endpoints were a composite clinical safety endpoint and an OCT healing index at 1 month (range: 0–98).Results: Eleven patients were included in the study. The study was prematurely terminated due to scaffold fractures and embolization of scaffold fragments in three cases requiring bailout stenting with drug‐eluting stents. One patient underwent bypass surgery at 3 months due to stenosis proximal to the study segment. All SB were patent for 1 month. One‐month OCT evaluation showed strut coverage of 96.9% and no malapposition. Scaffold fractures and uncovered jailing struts resulted in a less favorable mean OCT healing index score of 10.4 ± 9.0.Conclusions: Implanting a magnesium scaffold by the provisional technique in nontrue bifurcation lesions was associated with scaffold fracture, embolization of scaffold fragments, and a high need for bailout stenting.
- 30 December 2021
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 99 (4) , 1075-1083
Open AccessBioresorbable magnesium scaffold in the treatment of simple coronary bifurcation lesions: The BIFSORB pilot II study
Objectives: To evaluate the feasibility, safety, and healing response of a magnesium‐based bioresorbable scaffold (BRS) in the treatment of simple bifurcation lesions using the single stent provisional technique.Background: BRS may hold potential advantages in the treatment of coronary bifurcation lesions, however low radial strength and expansion capacity has been an issue with polymer‐based scaffolds. The magnesium BRS may prove suitable for bifurcation treatment as its mechanical properties are closer to those of permanent metallic drug‐eluting stents.Methods: The study was a proof‐of‐concept study with planned inclusion of 20 patients with stable angina pectoris and a bifurcation lesion involving a large side branch (SB) > 2.5 mm with less than 50% diameter stenosis. Procedure and healing response were evaluated by optical coherence tomography (OCT). The main endpoints were a composite clinical safety endpoint and an OCT healing index at 1 month (range: 0–98).Results: Eleven patients were included in the study. The study was prematurely terminated due to scaffold fractures and embolization of scaffold fragments in three cases requiring bailout stenting with drug‐eluting stents. One patient underwent bypass surgery at 3 months due to stenosis proximal to the study segment. All SB were patent for 1 month. One‐month OCT evaluation showed strut coverage of 96.9% and no malapposition. Scaffold fractures and uncovered jailing struts resulted in a less favorable mean OCT healing index score of 10.4 ± 9.0.Conclusions: Implanting a magnesium scaffold by the provisional technique in nontrue bifurcation lesions was associated with scaffold fracture, embolization of scaffold fragments, and a high need for bailout stenting.
- Open Access
- 11 November 2019
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 96 (7) , E674-E682
Mechanical properties of the drug‐eluting bioresorbable magnesium scaffold compared with polymeric scaffolds and a permanent metallic drug‐eluting stent
Objectives: To compare on the bench the physical and mechanical properties of Magmaris, a magnesium bioresorbable scaffold (BRS), with Absorb and DESolve polymeric BRS and a permanent metallic stent.Background: Understanding the mechanical and physical properties of BRS is crucial for appropriate implantation and postdilatation.Methods: Testing was performed in fluid at 37°C and in silicone bifurcation phantoms with a 30° angle between main branch (MB) and side branch.Results: The 3.0‐mm Magmaris BRS did not fracture after MB postdilatation up to 4.4 mm in contrast to the Absorb where the safe postdilatation diameter was 3.7 mm. For dilatation through stent cells, there were no Magmaris fractures with 3.0‐mm noncompliant (NC) balloons inflated to nominal pressure. Mini‐kissing balloon postdilatation with two 3.0‐mm NC balloons up to 17 atm was without fracture except for an outlier. Longitudinal and radial strengths were similar for Magmaris and Absorb BRS. The crossing profile for the Magmaris was larger than other devices. Recoil 120 min after deployment was the greatest for Magmaris but 120 min after 3.5 mm postdilatation all devices had similar diameters.Conclusions: The Magmaris BRS was more resistant to strut fracture than Absorb. It had a larger crossing profile than other devices and similar radial and longitudinal strengths to Absorb. While recoil after deployment was greater with Magmaris, 120 min after 3.5 mm postdilatation all devices had similar diameters.
- 11 November 2019
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 96 (7) , E674-E682
Open AccessMechanical properties of the drug‐eluting bioresorbable magnesium scaffold compared with polymeric scaffolds and a permanent metallic drug‐eluting stent
Objectives: To compare on the bench the physical and mechanical properties of Magmaris, a magnesium bioresorbable scaffold (BRS), with Absorb and DESolve polymeric BRS and a permanent metallic stent.Background: Understanding the mechanical and physical properties of BRS is crucial for appropriate implantation and postdilatation.Methods: Testing was performed in fluid at 37°C and in silicone bifurcation phantoms with a 30° angle between main branch (MB) and side branch.Results: The 3.0‐mm Magmaris BRS did not fracture after MB postdilatation up to 4.4 mm in contrast to the Absorb where the safe postdilatation diameter was 3.7 mm. For dilatation through stent cells, there were no Magmaris fractures with 3.0‐mm noncompliant (NC) balloons inflated to nominal pressure. Mini‐kissing balloon postdilatation with two 3.0‐mm NC balloons up to 17 atm was without fracture except for an outlier. Longitudinal and radial strengths were similar for Magmaris and Absorb BRS. The crossing profile for the Magmaris was larger than other devices. Recoil 120 min after deployment was the greatest for Magmaris but 120 min after 3.5 mm postdilatation all devices had similar diameters.Conclusions: The Magmaris BRS was more resistant to strut fracture than Absorb. It had a larger crossing profile than other devices and similar radial and longitudinal strengths to Absorb. While recoil after deployment was greater with Magmaris, 120 min after 3.5 mm postdilatation all devices had similar diameters.
- 4 May 2019
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 35 (7) , 1199-1210
Procedural findings and early healing response after implantation of a self-apposing bioresorbable scaffold in coronary bifurcation lesions
We aimed to evaluate feasibility, early healing and self-correcting properties of the Desolve 150 bioresorbable scaffold (BRS) implanted in bifurcation lesions, using the simple, provisional side branch (SB) stenting technique. BIFSORB pilot was a proof-of-concept study enrolling 10 patients with stable angina pectoris and a bifurcation lesion with SB ≥ 2.5 mm and less than 50% diameter stenosis. Procedure and 1-month outcome was evaluated by optical coherence tomography (OCT) to assess scaffold performance and healing patterns. Nine patients were treated with Desolve 150 BRS and one delivery to the target bifurcation failed. Thrombus formation in the jailed SB ostium was seen in three cases, but was completely resolved at 1-month. OCT confirmed acute self-correcting properties. No clinical events were reported after six months. Scaffold diameter by OCT increased in the proximal main vessel from 3.09 ± 0.16 mm to 3.34 ± 0.18 mm (p = 0.01) and in distal main vessel from 2.82 ± 0.26 mm to 3.02 ± 0.29 mm (p < 0.01) at one-month follow-up. SB ostial diameter stenosis improved from 42 ± 15% to 34 ± 12% (p = 0.01). Malapposition was effectively reduced after 1 month from 4.1 (1.4; 6.1)% to 0.1 (0; 0.6)% (p = 0.002). Treatment of bifurcation lesions using Desolve 150 BRS was feasible except for a delivery failure and unsettling thrombus formation behind jailing SB struts, which was completely resolved at 1-month. Self-correcting and even self-expanding properties were confirmed.
- 4 May 2019
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 35 (7) , 1199-1210
Procedural findings and early healing response after implantation of a self-apposing bioresorbable scaffold in coronary bifurcation lesions
We aimed to evaluate feasibility, early healing and self-correcting properties of the Desolve 150 bioresorbable scaffold (BRS) implanted in bifurcation lesions, using the simple, provisional side branch (SB) stenting technique. BIFSORB pilot was a proof-of-concept study enrolling 10 patients with stable angina pectoris and a bifurcation lesion with SB ≥ 2.5 mm and less than 50% diameter stenosis. Procedure and 1-month outcome was evaluated by optical coherence tomography (OCT) to assess scaffold performance and healing patterns. Nine patients were treated with Desolve 150 BRS and one delivery to the target bifurcation failed. Thrombus formation in the jailed SB ostium was seen in three cases, but was completely resolved at 1-month. OCT confirmed acute self-correcting properties. No clinical events were reported after six months. Scaffold diameter by OCT increased in the proximal main vessel from 3.09 ± 0.16 mm to 3.34 ± 0.18 mm (p = 0.01) and in distal main vessel from 2.82 ± 0.26 mm to 3.02 ± 0.29 mm (p < 0.01) at one-month follow-up. SB ostial diameter stenosis improved from 42 ± 15% to 34 ± 12% (p = 0.01). Malapposition was effectively reduced after 1 month from 4.1 (1.4; 6.1)% to 0.1 (0; 0.6)% (p = 0.002). Treatment of bifurcation lesions using Desolve 150 BRS was feasible except for a delivery failure and unsettling thrombus formation behind jailing SB struts, which was completely resolved at 1-month. Self-correcting and even self-expanding properties were confirmed.
- Open Access
- 8 December 2017
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 92 (5) , 883-889
Coronary balloon catheter tip damage. A bench study of a clinical problem
To confirm clinically that coronary balloon catheter tips may be damaged during bifurcation treatment with side-branch access through the side of a stent. On the bench, we aimed to assess the susceptibility of different balloon designs to damage. We compared catheter tip widths. We tested whether balloon tip flaring can cause stent distortion. We had observed that balloon catheters that failed to cross to a side-branch frequently exhibited tip damage. We examined microscopically for damage 82 balloon tips after clinical side-branch access. In a bench study, the forces required to compress catheter tips 0.5 mm were compared to assess susceptibility to damage. We compared tip widths of balloons of different nominal inflation diameters. We examined stents after side-branch access for distortion. In 42 of 48 (88%) of balloon tips from patients with resistance to or failure to cross through the side of a stent there was tip damage. Even when the balloon crossed without perceptible resistance, tip damage occurred in over half of balloons 18/34 (53%). Some balloon designs were more resistant to damage than others. Tips from balloons of different nominal diameters from the same manufacturer had the same width. Stent distortion caused by damaged balloon tips is improved by kissing balloon post-dilatation. Balloon tip damage is common with crossing between stent struts. This is one cause of failure of a balloon to access a side-branch and a new balloon should be used. If stent distortion is suspected, it should be corrected with kissing balloon post-dilatation.
- 8 December 2017
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 92 (5) , 883-889
Open AccessCoronary balloon catheter tip damage. A bench study of a clinical problem
To confirm clinically that coronary balloon catheter tips may be damaged during bifurcation treatment with side-branch access through the side of a stent. On the bench, we aimed to assess the susceptibility of different balloon designs to damage. We compared catheter tip widths. We tested whether balloon tip flaring can cause stent distortion. We had observed that balloon catheters that failed to cross to a side-branch frequently exhibited tip damage. We examined microscopically for damage 82 balloon tips after clinical side-branch access. In a bench study, the forces required to compress catheter tips 0.5 mm were compared to assess susceptibility to damage. We compared tip widths of balloons of different nominal inflation diameters. We examined stents after side-branch access for distortion. In 42 of 48 (88%) of balloon tips from patients with resistance to or failure to cross through the side of a stent there was tip damage. Even when the balloon crossed without perceptible resistance, tip damage occurred in over half of balloons 18/34 (53%). Some balloon designs were more resistant to damage than others. Tips from balloons of different nominal diameters from the same manufacturer had the same width. Stent distortion caused by damaged balloon tips is improved by kissing balloon post-dilatation. Balloon tip damage is common with crossing between stent struts. This is one cause of failure of a balloon to access a side-branch and a new balloon should be used. If stent distortion is suspected, it should be corrected with kissing balloon post-dilatation.
- 1 October 2017
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 10 (10) , e005677
Restenosis in a Collapsed Magnesium Bioresorbable Scaffold
Optical coherence tomography (OCT) may provide important mechanistic information in restenosis after treatment using bioresorbable scaffolds (BRS). Here, we present the signature findings by OCT of a novel magnesium BRS with in-segment restenosis 7 months postimplantation. A 65-year-old male presenting with stable angina was treated for a 95% stenosis in the proximal left anterior descending artery. The lesion was predilated with a semicompliant balloon 2.5×12 mm and a scoring balloon 3.0×13 mm before implanting a 3.5×15 mm magnesium BRS (Magmaris; Biotronik AG, Bülach, Switzerland) carefully sized by OCT. The magnesium BRS was postdilated using a 3.75×8 mm noncompliant balloon. Final angiography and OCT showed good expansion and apposition of the scaffold without …
- 1 October 2017
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 10 (10) , e005677
Restenosis in a Collapsed Magnesium Bioresorbable Scaffold
Optical coherence tomography (OCT) may provide important mechanistic information in restenosis after treatment using bioresorbable scaffolds (BRS). Here, we present the signature findings by OCT of a novel magnesium BRS with in-segment restenosis 7 months postimplantation. A 65-year-old male presenting with stable angina was treated for a 95% stenosis in the proximal left anterior descending artery. The lesion was predilated with a semicompliant balloon 2.5×12 mm and a scoring balloon 3.0×13 mm before implanting a 3.5×15 mm magnesium BRS (Magmaris; Biotronik AG, Bülach, Switzerland) carefully sized by OCT. The magnesium BRS was postdilated using a 3.75×8 mm noncompliant balloon. Final angiography and OCT showed good expansion and apposition of the scaffold without …